{"id":66602,"date":"2026-05-28T21:35:43","date_gmt":"2026-05-28T13:35:43","guid":{"rendered":"https:\/\/flcube.com\/?p=66602"},"modified":"2026-05-28T21:35:44","modified_gmt":"2026-05-28T13:35:44","slug":"roche-launches-liver-disease-panel-digital-algorithms-combine-biomarker-diagnostics-with-ce-certified-liverpro-to-transform-chronic-liver-disease-management","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66602","title":{"rendered":"Roche Launches Liver Disease Panel \u2013 Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Roche Holding AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROP:SWX\">SWX: ROP<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) announced the launch of its <strong>Liver Disease Panel<\/strong>, a certified suite of digital algorithms designed to enhance clinical identification and management of <strong>chronic liver disease (CLD)<\/strong>. The comprehensive solution spans the disease spectrum from <strong>metabolic dysfunction-associated steatotic liver disease (MASLD)<\/strong> through <strong>metabolic dysfunction-associated steatohepatitis (MASH)<\/strong> to <strong>hepatocellular carcinoma (HCC)<\/strong>, addressing critical gaps in early detection and surveillance.<\/p>\n\n\n\n<h2 id=\"h-product-portfolio-overview\" class=\"wp-block-heading\">Product Portfolio Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Liver Disease Panel \u2013 integrated digital diagnostic suite<\/td><\/tr><tr><td><strong>Core Technology<\/strong><\/td><td>CE-certified LiverPRO algorithm combined with biomarker-based diagnostics<\/td><\/tr><tr><td><strong>Target Conditions<\/strong><\/td><td>\u2022 MASLD<br>\u2022 MASH<br>\u2022 Hepatocellular carcinoma (HCC)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>CE-certified (LiverPRO algorithm)<\/td><\/tr><tr><td><strong>Clinical Application<\/strong><\/td><td>Full spectrum care from fibrosis risk identification to liver cancer surveillance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-integration-amp-clinical-workflow\" class=\"wp-block-heading\">Technology Integration &amp; Clinical Workflow<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Modality Approach:<\/strong> Combines established biomarker-based diagnostic technologies with advanced digital algorithms<\/li>\n\n\n\n<li><strong>LiverPRO Algorithm:<\/strong> CE-certified digital tool providing evidence-based decision support<\/li>\n\n\n\n<li><strong>Risk Stratification:<\/strong> Enables timely identification of fibrosis risk in early-stage liver disease<\/li>\n\n\n\n<li><strong>Disease Progression Monitoring:<\/strong> Tracks patient trajectory from MASLD through MASH to potential HCC development<\/li>\n\n\n\n<li><strong>Surveillance Optimization:<\/strong> Enhances liver cancer screening protocols for high-risk populations<\/li>\n\n\n\n<li><strong>Clinical Decision Support:<\/strong> Provides actionable insights integrated into routine care pathways<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-addressing-unmet-needs-in-liver-disease-management\" class=\"wp-block-heading\">Addressing Unmet Needs in Liver Disease Management<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Clinical Challenge<\/th><th>Roche Liver Disease Panel Solution<\/th><\/tr><\/thead><tbody><tr><td><strong>Late Diagnosis<\/strong><\/td><td>Early fibrosis risk identification enables intervention before irreversible damage<\/td><\/tr><tr><td><strong>Disease Heterogeneity<\/strong><\/td><td>Comprehensive coverage across MASLD-MASH-HCC spectrum<\/td><\/tr><tr><td><strong>Monitoring Complexity<\/strong><\/td><td>Integrated digital-biomarker approach simplifies longitudinal assessment<\/td><\/tr><tr><td><strong>Resource Constraints<\/strong><\/td><td>Algorithm-driven triage optimizes specialist referral and surveillance resources<\/td><\/tr><tr><td><strong>Outcome Prediction<\/strong><\/td><td>Evidence-based risk stratification supports personalized management decisions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The panel represents a paradigm shift from reactive to proactive liver disease management, leveraging Roche&#8217;s expertise in both diagnostic biomarkers and digital health solutions.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-strategic-positioning\" class=\"wp-block-heading\">Market Context &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Liver Disease Burden:<\/strong> Estimated 1.5 billion people worldwide affected by chronic liver conditions<\/li>\n\n\n\n<li><strong>MASLD\/MASH Epidemic:<\/strong> Prevalence increasing in parallel with global obesity and metabolic syndrome trends<\/li>\n\n\n\n<li><strong>Diagnostic Gap:<\/strong> Current methods (biopsy, imaging) limited by cost, accessibility, and invasiveness<\/li>\n\n\n\n<li><strong>Digital Health Integration:<\/strong> Aligns with healthcare systems&#8217; shift toward value-based, preventive care models<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Roche&#8217;s integrated approach combines proprietary biomarkers with certified algorithms<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-implementation-strategy\" class=\"wp-block-heading\">Commercial Implementation Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Healthcare System Adoption:<\/strong> Targeted at hospitals, hepatology centers, and primary care networks<\/li>\n\n\n\n<li><strong>Reimbursement Pathway:<\/strong> CE certification supports European market access and reimbursement discussions<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Platform designed for adaptation to regional guidelines and regulatory requirements<\/li>\n\n\n\n<li><strong>Data Integration:<\/strong> Compatible with existing electronic health record systems and laboratory information systems<\/li>\n\n\n\n<li><strong>Clinical Validation:<\/strong> Ongoing studies to demonstrate impact on patient outcomes and healthcare utilization<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Roche&#8217;s Liver Disease Panel commercial prospects, including market adoption, regulatory pathways, and clinical impact. Actual results may differ due to risks including competitive dynamics, reimbursement challenges, healthcare system integration barriers, and evolving clinical guidelines for liver disease management.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced the launch of its Liver Disease Panel,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[940,163,939],"class_list":["post-66602","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-otcmkts-rhhby","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche Launches Liver Disease Panel \u2013 Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced the launch of its Liver Disease Panel, a certified suite of digital algorithms designed to enhance clinical identification and management of chronic liver disease (CLD). The comprehensive solution spans the disease spectrum from metabolic dysfunction-associated steatotic liver disease (MASLD) through metabolic dysfunction-associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC), addressing critical gaps in early detection and surveillance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66602\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche Launches Liver Disease Panel \u2013 Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management\" \/>\n<meta property=\"og:description\" content=\"Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced the launch of its Liver Disease Panel, a certified suite of digital algorithms designed to enhance clinical identification and management of chronic liver disease (CLD). The comprehensive solution spans the disease spectrum from metabolic dysfunction-associated steatotic liver disease (MASLD) through metabolic dysfunction-associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC), addressing critical gaps in early detection and surveillance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66602\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T13:35:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-28T13:35:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66602#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66602\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche Launches Liver Disease Panel \u2013 Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management\",\"datePublished\":\"2026-05-28T13:35:43+00:00\",\"dateModified\":\"2026-05-28T13:35:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66602\"},\"wordCount\":478,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"OTCMKTS: RHHBY\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66602#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66602\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66602\",\"name\":\"Roche Launches Liver Disease Panel \u2013 Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-28T13:35:43+00:00\",\"dateModified\":\"2026-05-28T13:35:44+00:00\",\"description\":\"Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced the launch of its Liver Disease Panel, a certified suite of digital algorithms designed to enhance clinical identification and management of chronic liver disease (CLD). The comprehensive solution spans the disease spectrum from metabolic dysfunction-associated steatotic liver disease (MASLD) through metabolic dysfunction-associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC), addressing critical gaps in early detection and surveillance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66602#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66602\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66602#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche Launches Liver Disease Panel \u2013 Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche Launches Liver Disease Panel \u2013 Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management - Insight, China&#039;s Pharmaceutical Industry","description":"Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced the launch of its Liver Disease Panel, a certified suite of digital algorithms designed to enhance clinical identification and management of chronic liver disease (CLD). The comprehensive solution spans the disease spectrum from metabolic dysfunction-associated steatotic liver disease (MASLD) through metabolic dysfunction-associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC), addressing critical gaps in early detection and surveillance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66602","og_locale":"en_US","og_type":"article","og_title":"Roche Launches Liver Disease Panel \u2013 Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management","og_description":"Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced the launch of its Liver Disease Panel, a certified suite of digital algorithms designed to enhance clinical identification and management of chronic liver disease (CLD). The comprehensive solution spans the disease spectrum from metabolic dysfunction-associated steatotic liver disease (MASLD) through metabolic dysfunction-associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC), addressing critical gaps in early detection and surveillance.","og_url":"https:\/\/flcube.com\/?p=66602","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-28T13:35:43+00:00","article_modified_time":"2026-05-28T13:35:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66602#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66602"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche Launches Liver Disease Panel \u2013 Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management","datePublished":"2026-05-28T13:35:43+00:00","dateModified":"2026-05-28T13:35:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66602"},"wordCount":478,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["OTCMKTS: RHHBY","Roche","SWX: ROP"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66602#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66602","url":"https:\/\/flcube.com\/?p=66602","name":"Roche Launches Liver Disease Panel \u2013 Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-28T13:35:43+00:00","dateModified":"2026-05-28T13:35:44+00:00","description":"Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced the launch of its Liver Disease Panel, a certified suite of digital algorithms designed to enhance clinical identification and management of chronic liver disease (CLD). The comprehensive solution spans the disease spectrum from metabolic dysfunction-associated steatotic liver disease (MASLD) through metabolic dysfunction-associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC), addressing critical gaps in early detection and surveillance.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66602#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66602"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66602#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche Launches Liver Disease Panel \u2013 Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66602"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66602\/revisions"}],"predecessor-version":[{"id":66604,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66602\/revisions\/66604"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}